Psoriasis treatment patterns: a retrospective claims study

References

• National Psoriasis Foundation. About psoriasis [Internet] [cited 2017 Aug 16]. Available from: https://www.psoriasis.org/document.doc?id=793
   Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
   PubMed Web of Science ®Google Scholar
• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512–516.
   PubMed Web of Science ®Google Scholar
• American Academy of Dermatology. Psoriasis [Internet] [cited 2017 Aug 16]. Available from: https://www.aad.org/media/stats/conditions/psoriasis
   Google Scholar
• Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatol. 2005;210:194–199.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76:290–298.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Feldman SR, Chen L, et al. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. Curr Med Res Opin. 2008;24:3493–3501.
   PubMed Web of Science ®Google Scholar
• Thayer S, Watson C, Song R, et al. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis. J Med Econ. 2010;13:228–235.
   PubMedGoogle Scholar
• Yeaw J, Watson C, Fox KM, et al. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample. Adv Ther. 2014;31:410–425.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Therapy. 2012;29:664–674.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Johnson BH, Fox KM, et al. Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting. J Dermatolog Treat. 2013;24:369–373.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Koning JW, Rowse S, et al. Initiation, switching, and cessation of psoriasis treatments among patients with moderate to severe psoriasis in the United States. Clin Drug Investig. 2017;37:493–501.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Zhao Y, Navaratnam P, et al. Patterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasis. JMCP. 2015;21:201–209.
   PubMedGoogle Scholar
• Chastek B, Fox KM, Watson C, et al. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat. 2013;24:25–33.
   PubMed Web of Science ®Google Scholar
• Howe A, Eyck LT, Dufour R, et al. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm. 2014;20:1236–1244.
   PubMed Web of Science ®Google Scholar
• Sauer BC, Teng CC, He T, et al. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis. J Med Econ. 2016;19:34–43.
   PubMed Web of Science ®Google Scholar
• Cao Z, Carter C, Wilson KL, et al. Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2015;26:113–120.
   PubMed Web of Science ®Google Scholar
• Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74:1057–1065.
   PubMed Web of Science ®Google Scholar
• Carter C, Wilson KL, Smith D, et al. Comparative treatment patterns among psoriasis patients using adalimumab, etanercept, or ustekinumab. Am J Pharm Benefits. 2016;8:191–198.
   Web of Science ®Google Scholar
• Foster SA, Zhu B, Guo J, et al. Patient characteristics, health care resource utilization, and costs associated with treatment-regimen failure with biologics in the treatment of psoriasis. JMCP. 2016;22:396–405.
   PubMedGoogle Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80:27–40.
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80:43–53.
   PubMed Web of Science ®Google Scholar
• Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
   PubMed Web of Science ®Google Scholar
• DiMatteo MR. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care. 2004;42:200–209.
   PubMed Web of Science ®Google Scholar
• DiMatteo MR. Social support and patient adherence to medical treatment: a meta‐analysis. Health Psychol. 2004;23:207–218.
   PubMed Web of Science ®Google Scholar
• Czarnecka-Operacz M, Sadowska-Przytocka A. The possibilities and principles of methotrexate treatment of psoriasis – the updated knowledge. PDIA. 2014;31:392–400.
   Google Scholar
• Del Rosso JQ, Kircik L. Oral apremilast for the treatment of plaque psoriasis. J Clin Aesthet Dermatol. 2016;9:43–48.
   PubMedGoogle Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022.
   PubMed Web of Science ®Google Scholar
• Scherl EJ, Kumar S, Warren RU. Review of the safety and efficacy of ustekinumab. Therap Adv Gastroenterol. 2010;3:321–328.
   PubMedGoogle Scholar
• Tabolli S, Giannantoni P, Paradisi A, et al. The ‘switcher’ patient profile in psoriasis treatment: from traditional to biological from biological to traditional systemic drugs. Br J Dermatol. 2015;173:256–258.
   PubMed Web of Science ®Google Scholar
• Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68:64–72.
   PubMed Web of Science ®Google Scholar
• Schaarschmidt ML, Umar N, Schmieder A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2013;27:187–198.
   PubMed Web of Science ®Google Scholar
• Alcusky M, Lee S, Lau G, et al. Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis. Dermatol Ther (Heidelb). 2017;7:463–483.
   PubMed Web of Science ®Google Scholar